425: Rezolve AI Slams Commerce.com's "Poison Pill"

Rezolve AI criticizes Commerce.com's adoption of a stockholder rights plan as a "desperate" move to entrench the board and dilute shareholders, ahead of a May 14th election.

Summary

• Rezolve AI is strongly opposing Commerce.com's recent adoption of a "poison pill" (stockholder rights plan).
• Rezolve AI views this action as a tactic by the Commerce.com Board to protect its position and prevent shareholders from considering Rezolve AI's offer.
• Commerce.com's valuation of Rezolve AI's offer is based on a single day's closing price, ignoring analyst targets and contracted revenue.
• The Commerce.com Board has overseen a 96% decline in the company's stock price.
• Rezolve AI believes this move will dilute shareholders and hinder growth, and that shareholders will have an opportunity to voice their dissatisfaction at the May 14th election.
• Rezolve AI plans to assess the legality and fiduciary duty compliance of the Rights Plan.
• Rezolve AI will host an investor call on April 15, 2026, to discuss the situation.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative sentiment due to the aggressive public dispute, accusations of board entrenchment, and significant shareholder value destruction at Commerce.com.

Positives

• Rezolve AI highlights its contracted 2026 revenue of $232 million and full-year guidance of $360 million, representing 7.5 times year-on-year growth.
• Rezolve AI projects that a combined platform would command a materially higher trading multiple.
• Rezolve AI states it does not need Commerce.com to execute its strategy and is scaling rapidly independently.
• Rezolve AI has secured $750 million in total funding.

Negatives

• Commerce.com's Board has presided over a 96% decline in the company's stock price from its post-IPO peak.
• Commerce.com shareholders are in an illiquid position with limited exit options at the current $2.50 share price.
• Rezolve AI alleges Commerce.com's Board is attempting to prevent shareholders from considering a value-maximizing exchange offer.
• Rezolve AI claims Commerce.com's platform is falling behind and lacks a credible path to AI-native infrastructure under current management.

Risks

• The Commerce.com Board's adoption of a poison pill could dilute shareholders and stagnate growth.
• The effectiveness and legality of Commerce.com's poison pill are being questioned by Rezolve AI.
• The potential transaction between Rezolve AI and Commerce.com faces uncertainties regarding cooperation, approvals, and integration challenges.
• Competition and changes in applicable laws or regulations could impact Rezolve AI's growth and profitability.
• Economic weakness, market trends, and other external factors could affect Rezolve AI's operations.

Future Outlook

Rezolve AI is scaling rapidly and extending its leadership in AI-driven commerce, with or without Commerce.com. The company anticipates a combined platform would command a higher trading multiple and offers significant growth potential. Rezolve AI is assessing the legality of Commerce.com's poison pill and will provide further updates.

Management Comments

• "One week after Rezolve Ai took its case directly to Commerce.com's shareholders, their Board's response was not engagement, not dialogue, not a counter-proposal - it was the adoption of a poison pill," said Daniel M Wagner, CEO of Rezolve Ai.
• "A Board forecasting growth of 1.5% has chosen to try to lock its shareholders out of a proposal that implies more than double the current share price, rather than let them decide for themselves. The Commerce.com Board has poisoned its own well."
• "Commerce.com has chosen entrenchment over transformation, a decision that serves neither its shareholders nor the merchants whose businesses depend on its platform."
• "Let me be equally clear about the underlying reality: Rezolve does not need Commerce.com to execute its strategy. With or without Commerce.com, Rezolve Ai is scaling rapidly and extending its leadership in AI-driven commerce."
• "Commerce.com shareholders deserve the opportunity to evaluate the attractiveness of our proposed combination."
• "Tomorrow morning, at 0800 ET, I will be speaking directly to the people who actually own this company - because a poison pill is not a strategy, and this board knows it."

Industry Context

StockSavvy.ai notes that the aggressive response from Rezolve AI highlights a contentious M&A environment, particularly in the AI and e-commerce sectors where companies are vying for market leadership and technological integration. The adoption of a poison pill by Commerce.com, as criticized by Rezolve AI, is a defensive tactic often seen when a board feels threatened by an unsolicited offer or activist investor, especially when facing significant shareholder dissatisfaction due to stock performance.

Corporate Governance

Legal Proceedings

• Rezolve AI is assessing whether Commerce.com's Rights Plan complies with applicable law and its board's fiduciary duties.

Stakeholder Impact

• Shareholders of Commerce.com are potentially facing dilution and are being prevented from considering an offer that Rezolve AI claims offers material upside.
• Merchants using Commerce.com's platform are affected by the platform falling behind and lacking AI-native infrastructure under current management.
• Rezolve AI shareholders are being informed of the company's aggressive stance and strategic outlook.

Next Steps

• Rezolve AI will assess the legality and fiduciary duty compliance of Commerce.com's Rights Plan.
• Rezolve AI will provide a further update after reviewing Commerce.com's Form 8-K filing.
• Rezolve AI will host an investor call on April 15, 2026.
• Shareholders will have the opportunity to express views on the Commerce.com Board's leadership at the May 14, 2026, annual meeting.

Key Dates

Recommendation

The filing details a contentious situation where Rezolve AI is actively opposing Commerce.com's defensive tactics. While Rezolve AI presents strong growth figures and a compelling offer, the outcome of the potential transaction and the effectiveness of Commerce.com's poison pill remain uncertain. Investors should hold to await further developments, including the outcome of the director election and any potential legal challenges or revised offers.

Keywords

Rezolve AI, Commerce.com, Poison Pill, Stockholder Rights Plan, Merger, Acquisition, Shareholder Value, Corporate Governance, AI, E-commerce, SEC Filing, 425 Filing